Corbus Pharmaceuticals Holdings Inc

NASDAQ: CRBP
$16.73
+$0.65 (+4.0%)
Closing Price on November 21, 2024

CRBP Stock Chart and Intraday Price

CRBP Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 100 RIVER RIDGE DRIVE, NORWOOD, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 361.79M USD
Shares Outstanding 10,336,800
Corbus Pharmaceuticals Holdings Inc is a pioneering biopharmaceutical company focused on creating innovative treatments for serious illnesses. With a robust pipeline that includes CRB-701, a targeted therapy for cancer, and lenabasum, a novel treatment for inflammation and fibrosis, Corbus is at the forefront of medical research. The company also explores treatments for obesity and related metabolic diseases with CRB-913. Based in Norwood, Massachusetts, and founded in 2009, Corbus is committed to advancing healthcare through groundbreaking research and partnerships, such as its collaboration with Jenrin Discovery, LLC.

CRBP Articles

An Airline, Biotechs, and More See Huge Insider Buying
Public offerings of stock and activist investor activity prompted some huge insider buying at an entertainment company, an airline, biotechs, and more.
Trey Thoelcke
Published:

Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More
A public offering of shares this past week prompted a huge purchase from a beneficial owner. Meanwhile, a couple of repeat buyers further boosted their stakes as well.
Trey Thoelcke
Published:

3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry. The...
Rich Duprey
Published:

Buffett Can't Get Enough of This Stock, Plus Other Insider Buying
Warren Buffett boosts his stake in this tracking stock again, plus notable insider buying of communication and aviation stocks in the past week.
Trey Thoelcke
Published:

Another Huge Buffett Purchase Highlights Recent Insider Buying
Another huge Warren Buffett purchase highlighted the past week's insider buying, and a couple of IPOs also prompted insiders to action.
Trey Thoelcke
Published:

Insider Buying at These Biotechs Is Huge
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Trey Thoelcke
Published:

These Are The Robinhood Stocks With The Highest Analyst Rating
Robinhood has become the dominant discount brokerage platform over the last year. It had 4.3 million average revenue trades in June, which is a critical metric in the industry. This is higher than...
Douglas A. McIntyre
Published: